microRNA Replacement Therapy
Press Releases

 
Press Releases
Date Title and Summary View
05-12-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today reported financial results for the first quarter of 2016 and provided an update on recent developments. ...
04-25-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the appointment of Vincent J. O'Neill, M.D., B.Sc., M.R.C.P. as Chief Medical Officer, effective April 2...
04-20-16 Results reported in two poster presentations suggest MRX34 combination regimens may enhance effectiveness of standard cancer therapies AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of m...
03-29-16 Management to host conference call and webcast today at 5 p.m. Eastern AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today reported financial results for...
03-22-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced that the Company will host a conference call and live webcast on Tuesday, March 29, 2016 at 5:00 p.m. ET...
02-03-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced its participation in two healthcare investor conferences during the month of February. C...
02-01-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the appointment of Peter Greenleaf to the Company's Board of Directors. Mr. Greenleaf brings over 20 yea...
12-02-15 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced that President and Chief Executive Officer Paul Lammers, M.D., M.Sc., will present a corporate overview ...
11-23-15 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapies, today announced that the Journal of the National Cancer Institute (JNCI) published new preclinical data demonstrating a nov...
11-13-15 Demonstrated confirmed partial responses in liver cancer and melanoma in Phase 1 clinical trial of lead product candidate MRX34 Completed IPO and concurrent private placement in October with aggregate gross proceeds of $65.5 million Strengthened management team with...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
© 2017 Mirna Therapeutics, Inc. All Rights Reserved.